<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0011010'>Chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) is a <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disease</z:e> close to, but separate from both <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and may show either myeloproliferative (MP-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) or myelodysplastic (MD-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) features </plain></SENT>
<SENT sid="1" pm="."><plain>Not much is known about the molecular biology of this disease </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We studied a series of 30 CMML samples (13 MP- and 11 MD-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMMLs</z:e>, and 6 acutely transformed cases) from 29 patients by using Agilent high density array-comparative genomic hybridization (aCGH) and sequencing of 12 candidate genes </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Two-thirds of samples did not show any obvious alteration of aCGH profiles </plain></SENT>
<SENT sid="4" pm="."><plain>In one-third we observed chromosome abnormalities (e.g. <z:mp ids='MP_0004027'>trisomy</z:mp> 8, del20q) and gain or loss of genes (e.g. NF1, RB1 and CDK6) </plain></SENT>
<SENT sid="5" pm="."><plain><z:mp ids='MP_0011356'>RAS</z:mp> mutations were detected in 4 cases (including an uncommon codon 146 mutation in KRAS) and PTPN11 mutations in 3 cases </plain></SENT>
<SENT sid="6" pm="."><plain>We detected 11 RUNX1 alterations (9 mutations and 2 rearrangements) </plain></SENT>
<SENT sid="7" pm="."><plain>The rearrangements were a new, cryptic inversion of chromosomal region 21q21-22 leading to break and fusion of RUNX1 to USP16 </plain></SENT>
<SENT sid="8" pm="."><plain><z:mp ids='MP_0011356'>RAS</z:mp> and RUNX1 alterations were not mutually exclusive </plain></SENT>
<SENT sid="9" pm="."><plain><z:mp ids='MP_0011356'>RAS</z:mp> pathway mutations occurred in MP-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMMLs</z:e> (approximately 46%) but not in MD-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMMLs</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>RUNX1 alterations (mutations and cryptic rearrangement) occurred in both MP and MD classes (~38%) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: We detected <z:mp ids='MP_0011356'>RAS</z:mp> pathway mutations and RUNX1 alterations </plain></SENT>
<SENT sid="12" pm="."><plain>The latter included a new cryptic USP16-RUNX1 fusion </plain></SENT>
<SENT sid="13" pm="."><plain>In some samples, two alterations coexisted already at this early <z:hpo ids='HP_0011010'>chronic</z:hpo> stage </plain></SENT>
</text></document>